Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized Phase III trial of enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer

Next Previous
Trial Profile

A multicenter randomized Phase III trial of enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Abiraterone; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms EN-AB-LE Study for PCa; ENABLE

Most Recent Events

  • 03 Jun 2025 Results(n=92) evaluating efficacy and safety of Enzalutamide and Abiraterone plus Prednisolone published in the Prostate.
  • 01 Jan 2025 Results of Sub-analysis analyzing the efficacy of modified dose of enzalutamide and abiraterone plus prednisolone in ENABLE study published in the Prostate.
  • 27 Jan 2024 Results of Sub-analysis analyzing the efficacy of modified dose in ENABLE study castration-resistant prostate cancer presented at the 2024 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top